Supplementary valproate therapy for glioma patients: An alternative opportunity to enhance the efficiency of radio-chemotherapy

CONCLUSION: Our results show that valproate increases the PFS and OS period of glioma patients in comparison to other antiepileptic drugs. Our data suggest that the use of valproic acid should be considered as a first-line antiepileptic agent in certain well-selected epileptic patients with glioma as a supplement to the oncotherapy. Orv Hetil. 2021; 162(24): 960-967.PMID:34120100 | DOI:10.1556/650.2021.32110

Source: Orvosi Hetilap - June 13, 2021 Category: General Medicine Authors: Tam ás Mezei D ávid Mészáros P éter Pollner Attila Bag ó Imre Fedorcs ák P éter Banczerowski L ászló Sipos Source Type: research